Dermata Therapeutics, Inc. (NASDAQ:DRMA)
| Market Cap | 4.34M-77.0% |
| Revenue (ttm) | 0 |
| Net Income | -8.37M+19.0% |
| EPS | -4.39+90.6% |
| Shares Out | 4.02M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 284.949 |
| Open | 1.10 |
| Previous Close | 1.12 |
| Day's Range | 1.08 - 1.10 |
| 52-Week Range | 0.95 - 9.90 |
| Beta | 0.66 |
| Analysts | Buy |
| Price Target | 6.00(+455.56%) |
| Earnings Date | Nov 18, 2026 |
Insiders here have filed 2 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About DRMA
Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$DRMA stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in DRMA holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by DRMA's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
DRMA Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New DRMA patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to DRMA from public contracts
Source: USAspending.gov
DRMA Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from DRMA’s recent data — informational, not investment advice